Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Zogenix (ZGNX) Stock Price

Headlines about Zogenix (NASDAQ:ZGNX) have been trending somewhat positive on Thursday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zogenix earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.7791535275996 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Zogenix (NASDAQ:ZGNX) opened at $34.75 on Thursday. Zogenix has a one year low of $7.70 and a one year high of $43.35. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.71 and a current ratio of 2.71. The company has a market cap of $1,100.00, a PE ratio of -7.92 and a beta of 1.96.

A number of equities analysts have issued reports on ZGNX shares. Stifel Nicolaus reiterated a “buy” rating and set a $55.00 target price (up previously from $26.00) on shares of Zogenix in a report on Friday, September 29th. Mizuho reiterated a “buy” rating and set a $51.00 target price on shares of Zogenix in a report on Thursday, December 7th. William Blair upgraded shares of Zogenix from a “market perform” rating to an “outperform” rating in a research note on Friday, September 29th. Leerink Swann restated an “outperform” rating and set a $50.00 price objective (up from $20.00) on shares of Zogenix in a research note on Monday, October 2nd. Finally, JMP Securities initiated coverage on shares of Zogenix in a research note on Monday, November 27th. They set an “outperform” rating and a $56.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $42.67.

In related news, Director Roger Hawley sold 11,797 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $37.02, for a total value of $436,724.94. Following the completion of the sale, the director now directly owns 105,575 shares in the company, valued at approximately $3,908,386.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Bradley S. Galer purchased 1,346 shares of the stock in a transaction on Wednesday, December 13th. The stock was bought at an average cost of $36.59 per share, for a total transaction of $49,250.14. The disclosure for this purchase can be found here. Company insiders own 6.60% of the company’s stock.

WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Zogenix (ZGNX) Stock Price” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-zogenix-zgnx-stock-price.html.

About Zogenix

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Insider Buying and Selling by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply